Dr. Lal Pathlabs

₹3076.9 57.8 | 1.9%

WEBSITE BSE:539524 NSE : LALPATHLAB 26 Jul, 16:01

Market Cap ₹25686 Cr.

Stock P/E 71.8

P/B 14.3

Current Price ₹3076.9

Book Value ₹ 215.4

Face Value 10

52W High ₹3095

Dividend Yield 0.78%

52W Low ₹ 1943.2

Edit Ratio

Dr. Lal Pathlabs Research see more...

EQUITY RESEARCH: DR LALPATHLABS

Overview Inc. Year: 1995Industry: Hospital & Healthcare Services

Dr. Lal PathLabs Ltd is an India-based organisation, that is engaged in offering diagnostic and associated healthcare assessments and offerings. It has a community that have a National Reference Laboratory in New Delhi, a Reference Laboratory in Kolkata and approximately 229 other clinical laboratories. The Company is engaged specially within the enterprise of strolling laboratories for carrying out pathological investigations of diverse branches of biochemistry, haematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and different pathological and radiological investigations. The Company offers various tests by condition, which incorporates allergic reaction, diabetes, health checkups, viral infections, fever, heart sicknesses, high blood pressure, cancer, abortions, anaemia, arthritis, breast cancer, diphtheria, disease of liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular sickness and viral infections.

Dr. Lal Pathlabs Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Dr. Lal Pathlabs Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	497	486	503	534	489	491	541	601	539	545
Other Income	12	12	8	9	11	14	14	18	18	18
Total Income	509	498	511	543	500	505	555	619	557	564
Total Expenditure	388	364	385	390	376	375	395	424	398	401
Operating Profit	121	133	126	153	124	130	161	196	159	163
Interest	9	12	9	11	9	9	8	8	7	7
Depreciation	31	38	36	39	38	38	35	36	36	37
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	82	84	81	103	77	83	118	152	116	120
Provision for Tax	23	21	23	30	23	26	34	42	34	34
Profit After Tax	58	62	58	72	54	57	84	111	82	86
Adjustments	-1	-1	-1	-1	-1	-0	-1	-1	-1	-1
Profit After Adjustments	57	61	58	72	53	57	83	109	81	85
Adjusted Earnings Per Share	6.9	7.4	6.9	8.6	6.3	6.8	9.9	13.1	9.7	10.1

Dr. Lal Pathlabs Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	558	660	791	912	1057	1203	1330	1581	2087	2017	2227	2226
Other Income	8	13	22	28	31	46	55	51	53	42	69	68
Total Income	566	673	813	940	1088	1249	1385	1633	2140	2059	2296	2295
Total Expenditure	419	504	584	675	793	910	987	1145	1527	1527	1617	1618
Operating Profit	147	168	229	265	295	340	399	488	613	532	678	679
Interest	0	0	0	1	1	1	15	16	30	38	29	30
Depreciation	27	28	28	28	33	38	73	77	108	150	144	144
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	119	140	201	237	261	301	311	394	475	344	505	506
Provision for Tax	39	43	67	81	90	100	83	98	125	103	143	144
Profit After Tax	80	96	133	156	172	200	228	296	350	241	362	363
Adjustments	-1	-1	-1	-1	-1	-1	-2	-5	-5	-2	-5	-4
Profit After Adjustments	80	96	132	155	171	199	226	292	345	239	358	358
Adjusted Earnings Per Share	14.3	16.8	16	18.6	20.5	23.9	27.1	35	41.4	28.6	42.9	42.8

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	10%	12%	13%	15%
Operating Profit CAGR	27%	12%	15%	17%
PAT CAGR	50%	7%	13%	16%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	27%	-5%	22%	NA%
ROE Average	21%	21%	23%	28%
ROCE Average	28%	27%	30%	38%

Dr. Lal Pathlabs Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	231	341	507	596	788	945	1033	1245	1502	1666	1849
Minority's Interest	2	2	3	2	4	5	21	31	35	33	36
Borrowings	0	0	0	0	0	0	0	0	167	83	0
Other Non-Current Liabilities	1	-5	12	-6	-9	-20	70	83	106	93	61
Total Current Liabilities	97	112	91	85	116	138	227	274	500	470	465
Total Liabilities	332	450	613	676	899	1069	1351	1633	2310	2345	2411
Fixed Assets	140	150	166	152	208	209	413	447	1369	1305	1194
Other Non-Current Assets	22	18	24	57	68	47	46	41	66	67	91
Total Current Assets	170	282	424	467	623	814	893	1145	875	973	1127
Total Assets	332	450	613	676	899	1069	1351	1633	2310	2345	2411

Dr. Lal Pathlabs Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	17	16	23	27	29	66	129	197	244	378	264
Cash Flow from Operating Activities	98	122	159	171	197	219	284	398	447	456	535
Cash Flow from Investing Activities	-90	-113	-163	-137	-172	-100	-26	-212	-449	-287	-24
Cash Flow from Financing Activities	-10	-1	0	-32	13	-55	-190	-139	136	-283	-414
Net Cash Inflow / Outflow	-2	8	-5	2	37	64	67	48	134	-114	97
Closing Cash & Cash Equivalent	16	23	19	29	66	129	197	244	378	264	361

Dr. Lal Pathlabs Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	14.3	16.77	15.99	18.61	20.49	23.9	27.11	34.99	41.37	28.65	42.85
CEPS(Rs)	20.03	22.81	19.54	22.05	24.58	28.64	36.04	44.84	55	46.93	60.6
DPS(Rs)	1.1	1.53	2.45	3	4.5	6	12	20	12	12	24
Book NAV/Share(Rs)	38.16	57.56	61.28	70.66	92.39	110.08	119.97	144.61	173.17	192.88	215.4
Core EBITDA Margin(%)	24.83	23.52	26.24	26.03	24.98	24.4	25.83	27.59	26.86	24.29	27.36
EBIT Margin(%)	21.4	21.24	25.43	26.03	24.8	25.04	24.49	25.95	24.2	18.91	24.02
Pre Tax Margin(%)	21.37	21.18	25.36	25.96	24.72	24.97	23.34	24.94	22.75	17.05	22.7
PAT Margin (%)	14.39	14.62	16.84	17.05	16.25	16.66	17.11	18.75	16.78	11.95	16.27
Cash Profit Margin (%)	19.27	18.89	20.41	20.07	19.38	19.83	22.58	23.63	21.96	19.4	22.72
ROA(%)	27.3	24.67	25.06	24.13	21.81	20.38	18.81	19.87	17.77	10.36	15.23
ROE(%)	43.95	37.14	32.45	28.45	25.32	23.76	23.74	26.89	26.45	15.8	21.27
ROCE(%)	60.49	48.87	47.43	43.07	37.9	34.78	32.94	36.03	32.67	20.34	27.89
Receivable days	14.7	15.53	15.51	15.62	14.32	14.31	14.35	13.63	13.3	14.14	12.15
Inventory Days	6.64	7.18	6.64	6.49	7.81	8.47	11.73	11.49	8.31	7.81	5.83
Payable days	99.7	87.86	80.66	87.64	95.14	101.04	120.69	120.3	105.92	123.86	138.53
PER(x)	0	0	57.63	51.99	42.7	44.12	51.69	77.38	63.02	63.8	52.8
Price/Book(x)	0	0	15.04	13.69	9.47	9.58	11.68	18.72	15.06	9.48	10.5
Dividend Yield(%)	0	0	0.27	0.31	0.51	0.57	0.86	0.74	0.46	0.66	1.06
EV/Net Sales(x)	-0.04	-0.1	9.36	8.55	6.6	6.9	8.35	13.68	10.28	7.34	8.15
EV/Core EBITDA(x)	-0.17	-0.4	32.28	29.42	23.63	24.43	27.87	44.38	34.99	27.86	26.74
Net Sales Growth(%)	23.53	18.22	19.97	15.3	15.84	13.86	10.55	18.86	32.01	-3.38	10.4
EBIT Growth(%)	48.07	17.35	43.6	18.04	10.37	14.96	8.11	25.96	23.09	-24.51	40.24
PAT Growth(%)	44.24	20.15	38.15	16.78	10.39	16.72	13.53	30.27	18.15	-31.18	50.28
EPS Growth(%)	46.02	17.26	-4.64	16.4	10.09	16.65	13.43	29.07	18.25	-30.75	49.58
Debt/Equity(x)	0	0	0	0	0	0	0	0	0.24	0.15	0.05
Current Ratio(x)	1.75	2.52	4.67	5.5	5.37	5.88	3.93	4.18	1.75	2.07	2.42
Quick Ratio(x)	1.64	2.39	4.51	5.29	5.14	5.68	3.68	4.02	1.65	2	2.34
Interest Cover(x)	603.05	346.2	404.57	340.29	311.72	359.22	21.28	25.65	16.74	10.16	18.22
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0.02	0.02	0

Dr. Lal Pathlabs Shareholding Pattern

#	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoter	55.23	55.05	55.05	55.05	55.03	55.01	54.61	54.6	54.6	54.6
FII	23.44	22.37	23.26	25.8	24.89	23.27	24.36	25.35	26.15	25.42
DII	6.83	6.52	6.27	6.19	6.55	8.63	9.14	9.56	9.69	12.71
Public	14.5	16.06	15.43	12.96	13.52	13.1	11.89	10.49	9.56	7.26
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoter	4.6	4.59	4.59	4.59	4.59	4.59	4.56	4.56	4.56	4.56
FII	1.95	1.86	1.94	2.15	2.08	1.94	2.03	2.12	2.18	2.12
DII	0.57	0.54	0.52	0.52	0.55	0.72	0.76	0.8	0.81	1.06
Public	1.21	1.34	1.29	1.08	1.13	1.09	0.99	0.88	0.8	0.61
Others	0	0	0	0	0	0	0	0	0	0
Total	8.33	8.34	8.34	8.34	8.34	8.34	8.35	8.35	8.35	8.35

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 21%
Company has reduced debt.
Company is almost debt free.

Cons

Debtor days have increased from 123.86 to 138.53days.
Stock is trading at 14.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Dr. Lal Pathlabs News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

Current Price: 135/-

Lakeshore Hospital

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Dr. Lal Pathlabs

Add Watchlist

Dr. Lal Pathlabs Research see more...

Overview Inc. Year: 1995Industry: Hospital & Healthcare Services

Dr. Lal Pathlabs Share Price

Alert Data

Quarterly Price

Peer Comparison

Dr. Lal Pathlabs Quarterly Results

Dr. Lal Pathlabs Profit & Loss

Growth Rates

Dr. Lal Pathlabs Balance Sheet

Dr. Lal Pathlabs Cash Flow

Dr. Lal Pathlabs Ratios

Dr. Lal Pathlabs Shareholding Pattern

Dr. Lal Pathlabs News

Top Unlisted Companies & InstaBuy Companies

Lakeshore Hospital

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!